Tradestie Institutional Equity Comparison Engine

SRZN vs EQ โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EQ Overall Edge

EQ Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Equillium, Inc. Common Stock (EQ) driven by superior Valuation, Growth & Margin while SRZN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus EQ at 1.5x Forward P/E and 0.0% operating margin (-52.3% YoY). In options structure, SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner EQ
SRZN N/M vs EQ 1.5x Fwd P/E
Growth & Margin Winner EQ
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs -52.3%
Momentum & Technical Winner SRZN
1Y +110.8% vs +5.0% ยท 52W Pos 63% vs 9%
Options & Structure Winner SRZN
CONSOLIDATION (13th %ile IV) vs UNCLASSIFIED (100th %ile IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
1M Return +10.52%
1Y Return +110.81%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.06
-5.36% 1D
Market Cap $92.2M
1M Return -16.54%
1Y Return +4.95%
Forward P/E 1.5x
Unified AI Score
48.6 / 100 HOLD
Tech 29.0 Fund 55.0 Flow 63.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +110.81% EQ +4.95% Spread: +105.86 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SRZN Revenue EQ Revenue SRZN Op. Margin EQ Op. Margin Margin Edge
FY2022 $10M $20M -354.7% -393.9% SRZN
FY2023 N/A $40M N/A -40.2% EQ
FY2024 $10M $40M -239.7% -20.1% EQ
FY2025 $0M N/A -1210.6% N/A SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (4) vs EQ (5)
Institutional Metric SRZN EQ Criterion Row Winner
Market Capitalization Scale $642.7M $92.2M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M 1.5x Lower Multiple EQ
Forward P/E Ratio Valuation N/M 1.5x Lower Multiple EQ
Revenue Growth (YoY) Growth +408.6% -52.3% Higher Growth SRZN
Operating Margin (TTM) Profitability -485.4% 0.0% Higher Margin EQ
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -59.0% Higher ROE EQ
52-Week Range Position Momentum 63% ($13โ€“$38) 9% ($1โ€“$4) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.29ฮฒ ยท 73% Vol 1.54ฮฒ ยท 89% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 36.0 / 100 (SELL) 48.6 / 100 (HOLD) Higher Composite EQ

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs EQ Buy Guide
SRZN CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live EQ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor EQ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.